SCHEMBL5582093

SCHEMBL5582093

CNc1ncc2c(-c3cccc(Cl)c3)cc(-c3ccc(C(=O)O)cc3O)c(OC)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 12/20 0.49
CSNK2A2 P19784 8/20 0.49
CSNK2B P67870 8/20 0.49
PTK2 Q05397 1/20 0.42
ADORA1 P30542 1/20 0.39
MAP4K4 O95819 1/20 0.39
LRRK2 Q5S007 1/20 0.38
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
TUBB2A Q13885 1/20 0.37
TUBB8 Q3ZCM7 1/20 0.37
TUBA3E Q6PEY2 1/20 0.37
TUBA1A Q71U36 1/20 0.37
TUBA1C Q9BQE3 1/20 0.37
TUBB6 Q9BUF5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5582053 0.93 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BPTK2ADORA1
SCHEMBL5581710 0.92 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BPTK2ADORA1
SCHEMBL5581846 0.92 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BPTK2ADORA1
SCHEMBL5581995 0.91 CSNK2A1 (0.50) CSNK2A1CSNK2A2CSNK2BPTK2ADORA1
SCHEMBL5582212 0.90 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BPTK2ADORA1
SCHEMBL5581541 0.88 CSNK2A1 (0.47) CSNK2A1CSNK2A2CSNK2BPTK2ADORA1
SCHEMBL5582247 0.87 ADORA1 (0.39) CSNK2A1CSNK2A2CSNK2BADORA1MAP4K4
SCHEMBL5581820 0.84 ADORA1 (0.43) CSNK2A1CSNK2A2CSNK2BADORA1MAP4K4
SCHEMBL5581799 0.84 FYN (0.41) CSNK2A1CSNK2A2CSNK2BADORA1MAP4K4
SCHEMBL5582071 0.83 FYN (0.39) CSNK2A1CSNK2A2CSNK2BADORA1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 CSNK2A1 602/4885CSNK2A2 467/4885CSNK2B 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.